0
0.5
1
1.5
2+
Mortality
6%
Improvement
Relative Risk
Ventilation
-1%
Mortality (b)
21%
Ventilation (b)
13%
Casirivimab/i.. Horby et al. LATE TREATMENT RCT
Is late treatment with casirivimab/imdevimab beneficial for COVID-19?
RCT 9,785 patients in the United Kingdom (September 2020 - May 2021)
No significant difference in outcomes seen
c19early.org
Horby et al., The Lancet, June 2021
Favors casirivimab/im..
Favors control